IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.137
NA - Nord America 4.079
AS - Asia 2.294
SA - Sud America 763
Continente sconosciuto - Info sul continente non disponibili 375
AF - Africa 65
OC - Oceania 3
Totale 11.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.969
RU - Federazione Russa 1.787
SG - Singapore 995
BR - Brasile 646
CN - Cina 592
IE - Irlanda 531
SE - Svezia 407
IT - Italia 339
PL - Polonia 315
HK - Hong Kong 253
DE - Germania 203
VN - Vietnam 137
FI - Finlandia 125
GB - Regno Unito 121
UA - Ucraina 111
FR - Francia 93
IN - India 61
BD - Bangladesh 55
CA - Canada 48
AR - Argentina 31
MX - Messico 31
NL - Olanda 28
JP - Giappone 26
IQ - Iraq 25
ID - Indonesia 22
EC - Ecuador 21
BE - Belgio 20
CO - Colombia 19
TR - Turchia 17
UZ - Uzbekistan 17
AT - Austria 15
ES - Italia 15
JO - Giordania 14
MA - Marocco 13
PY - Paraguay 13
ZA - Sudafrica 13
PK - Pakistan 10
JM - Giamaica 9
KE - Kenya 9
PE - Perù 8
CL - Cile 7
MY - Malesia 7
TH - Thailandia 7
VE - Venezuela 7
AZ - Azerbaigian 6
NP - Nepal 6
BO - Bolivia 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
TN - Tunisia 5
UY - Uruguay 5
CR - Costa Rica 4
IL - Israele 4
IR - Iran 4
LB - Libano 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
SA - Arabia Saudita 4
AL - Albania 3
AM - Armenia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
KG - Kirghizistan 3
LT - Lituania 3
NI - Nicaragua 3
RO - Romania 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
KW - Kuwait 2
NG - Nigeria 2
PS - Palestinian Territory 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CM - Camerun 1
GY - Guiana 1
IS - Islanda 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MZ - Mozambico 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
Totale 11.337
Salva come PNG Salva come JPEG
Città #
Ashburn 777
Singapore 575
Dublin 531
Moscow 522
Chandler 404
Dallas 326
Warsaw 315
Hong Kong 252
Nyköping 239
San Jose 225
Beijing 189
Jacksonville 162
Messina 150
Council Bluffs 148
Munich 127
Dearborn 98
Los Angeles 90
The Dalles 88
Princeton 84
Medford 73
Des Moines 60
New York 59
Ann Arbor 58
Lauterbourg 54
Lancaster 53
Cambridge 52
Helsinki 51
Houston 47
São Paulo 42
Boardman 34
Wilmington 34
Santa Clara 33
Redondo Beach 31
Ho Chi Minh City 29
Hanoi 28
Woodbridge 28
Buffalo 27
Seattle 27
Jinan 25
Rio de Janeiro 25
Dong Ket 24
Tianjin 24
San Mateo 23
Guangzhou 22
Shenyang 22
Tokyo 20
Orem 19
Brussels 18
Falls Church 18
Montreal 18
Rome 18
Columbus 16
Turku 16
Baghdad 15
Belo Horizonte 15
Brasília 15
Chicago 15
Nuremberg 15
Chennai 14
Jakarta 14
Milan 14
Tashkent 14
Shenzhen 13
Amman 12
Nanchang 12
Nanjing 12
Ningbo 12
Amsterdam 11
Atlanta 11
Phoenix 11
North Bergen 10
Shanghai 10
Stockholm 10
Boston 9
Brooklyn 9
Frankfurt am Main 9
Lappeenranta 9
Porto Alegre 9
Curitiba 8
Haikou 8
London 8
Pune 8
Toronto 8
Washington 8
Zhengzhou 8
Campinas 7
Dhaka 7
Goiânia 7
Hangzhou 7
Hải Dương 7
Johannesburg 7
Kunming 7
Medellín 7
Mexico City 7
Nairobi 7
Quito 7
Vienna 7
Aracaju 6
Asunción 6
Auburn Hills 6
Totale 6.888
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 294
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 292
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 230
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 221
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 219
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 218
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 211
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 201
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 195
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 195
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 186
Emerging markers of cachexia predict survival in cancer patients. 182
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 176
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 175
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 172
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 170
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 169
Kinase regulation of human MHC class i molecule expression on cancer cells 169
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 168
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 166
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 163
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 161
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 160
Congenital heart disease in down syndrome 159
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 157
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 150
Thyroid function, autoimmunity and nodules in hematological malignancies 149
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 145
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 141
The heart in Anderson-Fabry disease 141
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 140
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 137
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 135
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 131
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 128
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 125
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 121
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 120
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 118
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 118
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 117
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 117
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 117
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 116
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 112
null 111
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 111
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 110
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 108
null 107
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 106
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 106
null 105
null 105
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 101
null 99
null 96
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 96
null 95
null 93
Primary central nervous system lymphoma: Novel precision therapies 93
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 92
null 90
Emerging drugs for diffuse large B-cell lymphoma. 88
Insights into the tumor microenvironment of B cell lymphoma 87
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 84
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 84
null 81
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 79
null 79
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 77
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 77
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 76
null 75
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 74
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 72
null 72
Pim kinases in hematological malignancies: where are we now and where are we going? 70
null 67
null 66
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 64
null 64
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 63
Simplified risk stratification model for patients with Waldenström macroglobulinemia 62
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 56
null 46
R-CHOP versus R-COMP: are they really equally effective? 44
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 41
null 41
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 40
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts 40
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 37
null 35
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 33
null 33
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 31
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 31
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 30
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity 27
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma 26
Totale 11.363
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.446
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022512 0 0 19 19 30 19 20 19 8 104 66 208
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/20251.865 14 19 34 118 103 82 118 418 414 132 142 271
2025/20265.222 216 333 376 423 511 969 711 572 590 279 95 147
2026/2027490 192 242 56 0 0 0 0 0 0 0 0 0
Totale 11.716